INSULIN GLARGINE (LANTUS®)

International Journal of Clinical Practice - Tập 56 Số 6 - Trang 460-466 - 2002
Julie A. Owens1, S.M. Griffiths1
1Diabetes Research Unit, University of Wales College of Medicine, Cardiff

Tóm tắt

SUMMARYInsulin glargine (Lantus®) is a long‐acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available ‘intermediate‐acting’ insulins that are currently used for basal insulin supplementation. In contrast to NPH insulin, subcutaneous insulin glargine injected once daily provides a relatively constant basal level of circulating insulin with no pronounced peak. In patients with type 1 and type 2 diabetes, once‐daily insulin glargine achieves equivalent glycaemic control to NPH insulin given once or twice daily. In patients with type 1 diabetes, it is associated with significantly lower fasting blood glucose (FBG) levels, especially in those patients previously on twice‐daily NPH insulin. Insulin glargine is well tolerated and elicits less hypoglycaemia, especially nocturnal episodes, than NPH insulin, with similar levels of glycaemic control. This benefit is seen in patients with both type 1 and type 2 diabetes, in particular those previously on a once‐daily NPH insulin regimen. Patients with type 1 and type 2 diabetes have also reported higher levels of treatment satisfaction when treated with insulin glargine. Insulin glargine provides the opportunity to achieve target blood glucose levels more effectively and safely compared with NPH insulin, due to the reduced risk of hypoglycaemia, especially nocturnal hypoglycaemia. Insulin treatment needs to be individualised, with the dose of insulin glargine adjusted according to the blood glucose level as part of an aggressive regimen in an attempt to achieve near normoglycaemia without incurring episodes of hypoglycaemia. Insulin glargine should be used in combination with short‐acting insulin analogues in patients with type 1 diabetes. In patients where oral hypoglycaemic agents are failing, insulin glargine can be added. The early introduction of insulin in patients with type 2 diabetes is to be encouraged.

Từ khóa


Tài liệu tham khảo

10.1016/S0950-351X(05)80207-1

10.1530/eje.0.1380240

10.1016/S0140-6736(01)05842-1

Tappy L, 1995, Regulation of hepatic glucose production in healthy subjects and patients with non‐insulin dependent diabetes mellitus, Diabetes Metab, 21, 233

10.2337/diacare.15.6.737

10.1056/NEJM198908103210601

10.2337/diacare.21.9.1414

10.1136/bmj.316.7139.1221

10.2337/diacare.22.2.345

10.1016/0002-9343(91)90605-W

Lee W, 1998, From insulin to insulin analogs: progress in the treatment of type I diabetes, Diabet Rev, 6, 73

10.1016/0168-8227(95)01064-K

10.1136/bmj.321.7258.405

10.1016/S0140-6736(98)07019-6

10.1056/NEJM199309303291401

10.1001/jama.1996.03540170053032

10.2337/diacare.24.4.631

10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

10.2337/diacare.18.11.1510

10.1345/aph.17360

10.2174/1381612013397915

Rosskamp RH, 1999, Long‐acting insulin analogs, Diabetes Care, 22, B109

10.2337/diacare.16.3.71

Bendtson I, 1995, Nocturnal hypoglycaemia in patients with insulin‐dependent diabetes mellitus, Dan Med J, 42, 269

Scholtz H, 1999, An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique, Diabetologia, 42

10.1136/bmj.285.6336.159

10.1016/S0169-409X(98)00079-9

10.2337/diacare.23.5.644

10.1016/S0140-6736(00)02546-0

10.1007/s001250051286

10.2337/diabetes.49.12.2142

10.1517/13543784.8.3.307

10.2337/diacare.23.6.813

Luzio S, 1999, Comparison of the subcutaneous absorption of HOE 901 and NPH human insulin in pat type 2 diabetic subjects, Diabetes, 48, A111

Heise T, 2000, No evidence for accumulation of HOE901 after multiple injections in type 1 diabetic patients, Diabetologia, 43, A196

Kuerzel G, 2001, Kinetics and metabolite profile of insulin glargine (Lantus®), Diabetologia, 44, A208

10.1046/j.1463-1326.2000.00109.x

Seipke G, 1995, HOE901: a new insulin with prolonged action, Eur J Endocrinol, 132, 25

10.2337/diacare.23.5.639

10.2337/diacare.23.11.1666

10.2337/diacare.23.8.1130

10.2337/diacare.23.2.157

10.2337/diacare.23.8.1137

Hershon K, 2001, Beneficial effects of insulin glargine compared to NPH in subjects with type 1 diabetes, Diabetologia, 44, A15

Standi E, 2000, Comparison of insulin glargine (HOE 901) and NPH‐insulin in intensified therapy of type‐1 diabetics: results of an international, multi‐center, randomized 28‐week study, Exp Clin Endocrinol Diabetes, 108, A107

10.2337/diacare.24.11.2005

10.2337/diacare.23.4.557a

10.1046/j.1464-5491.2001.00529.x

Rosak C, for the HOE901/3002 study group, 2000, Comparison of insulin glargine (HOE 901) and NPH insulin in combination with oral antidiabetics for treatment of type 2 diabetic patients: results of an international multicentre, randomized 1‐year study, Exp Clin Endocrinol Diabetes, 108, A102

Matthews DR, 2001, Hypoglycaemia 2001: from research to practice, 101

Fonseca V, 2001, Less symptomatic hypoglycaemia with insulin glargine compared to NPH insulin in patients with type 2 diabetes, Diabetologia, 44, A207

Rosenstock J, 2001, Treatment to target study: feasibility of achieving control with the addition of basal bedtime insulin glargine (Lantus) or NPH insulin in insulin‐naive patients with type 2 diabetes on oral agents, Diabetes, 50, A129

Witthaus E, 2000, Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes (Abstract), Diabetologia, 43, A205

10.1042/bj3150271

Jorgensen L, 1992, Carcinogenic effect of the human insulin analogue B10Asp in female rats, Diabetologia, 35, 3

10.1055/s-2007-978849

10.1016/S0014-2999(96)00903-X

10.2337/diabetes.49.6.999

10.1210/jcem.86.12.8110

Stammberger I, 2001, Insulin glargine is not carcinogenic in rats and mice, Diabetes, 50, A429

10.2337/diacare.22.4.585

Forjanic‐Klapproth J, 2001, Progression of retinopathy with insulin glargine or NPH insulin: a multi‐trial analysis, Diabetologia, 44, A287

10.1136/bmj.315.7116.1105

Thông tin
Thông tin xuất bản

International Journal of Clinical Practice

Tập 56 Số 6

460-466

Thông tin tác giả